利福平在人结核病中的临床药代动力学与药效学
本文综述了利福平在成人结核病治疗中的药代动力学与药效学,涵盖不同剂量及影响暴露的因素;指出利福平暴露个体间和个体内变异大,Cmax>8.2 μg/mL是灭菌活性的独立预测因子,严重结核如结核性脑膜炎需Cmax≥22 μg/mL且AUC6≥70 μg·h/mL以降低死亡率,每日剂量高达35 mg/kg持续12周安全且耐受良好,建议未来短程方案研究考虑高剂量利福平。
要点
- 利福平Cmax>8.2 μg/mL是灭菌活性的独立预测因子,治疗药物监测可助优化剂量至≥8 μg/mL。
- 结核性脑膜炎需更高暴露:Cmax≥22 μg/mL且AUC6≥70 μg·h/mL与死亡率降低相关。
- 每日利福平剂量高达35 mg/kg持续12周安全且耐受良好,未来短程方案可考虑高剂量。
核心结论
- 利福平暴露个体间和个体内变异大,空腹给药可减少变异。
- Cmax>8.2 μg/mL是灭菌活性的独立预测因子。
- 每日剂量高达35 mg/kg持续12周安全且耐受良好,未来短程方案研究可考虑高剂量利福平。
研究设计与样本
- 本文为叙述性综述,回顾成人利福平在不同剂量下的药代动力学与药效学。
主要发现
- 利福平暴露受营养不良、HIV感染、糖尿病、剂量大小、药物遗传多态性、肝硬化及劣质药品等因素影响。
- 肾功能损害对600 mg剂量利福平的药代动力学无影响。
- 结核性脑膜炎患者Cmax≥22 μg/mL且AUC6≥70 μg·h/mL与死亡率降低相关。
- 每日利福平剂量高达35 mg/kg持续12周安全且耐受良好。
关键数值与推荐
- 利福平Cmax>8.2 μg/mL是灭菌活性的独立预测因子。
- 建议利福平浓度≥8 μg/mL,可在给药后2、4、6小时进行治疗药物监测。
- 结核性脑膜炎需Cmax≥22 μg/mL且AUC6≥70 μg·h/mL以降低死亡率。
- 每日利福平剂量高达35 mg/kg持续12周安全且耐受良好。
临床怎么用
- 可通过空腹给药减少利福平暴露变异。
- 治疗药物监测(给药后2、4、6小时)可助优化剂量以达到推荐浓度≥8 μg/mL。
- 结核性脑膜炎患者需更高暴露目标(Cmax≥22 μg/mL且AUC6≥70 μg·h/mL)。
- 未来短程方案研究可考虑高剂量利福平,并纳入Cmax/MIC和AUC/MIC等疗效替代指标。
局限性
- 需更多研究确认高于标准剂量的暴露能否转化为更快痰菌转阴、更高治愈率、更低复发率和更低死亡率。
- 未来研究应有足够把握度确定治疗结局,并纳入Cmax/MIC和AUC/MIC等疗效替代指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago was critical for shortening the treatment duration for patients with pulmonary TB to 6 months when combined with pyrazinamide in the first 2 months. Resistance or hypersensitivity to rifampicin effectively condemns a patient to prolonged, less effective, more toxic, and expensive regimens. Because of cost and fears of toxicity, rifampicin was introduced at an oral daily dose of 600 mg (8-12 mg/kg body weight). At this dose, clinical trials in 1970s found cure rates of ≥ 95% and relapse rates of < 5%. However, recent papers report lower cure rates that might be the consequence of increased emergence of resistance. Several lines of evidence suggest that higher rifampicin doses, if tolerated and safe, could shorten treatment duration even further. We conducted a narrative review of rifampicin pharmacokinetics and pharmacodynamics in adults across a range of doses and highlight variables that influence its pharmacokinetics/pharmacodynamics. Rifampicin exposure has considerable inter- and intra-individual variability that could be reduced by administration during fasting. Several factors including malnutrition, HIV infection, diabetes mellitus, dose size, pharmacogenetic polymorphisms, hepatic cirrhosis, and substandard medicinal products alter rifampicin exposure and/or efficacy. Renal impairment has no influence on rifampicin pharmacokinetics when dosed at 600 mg. Rifampicin maximum (peak) concentration (Cmax) > 8.2 μg/mL is an independent predictor of sterilizing activity and therapeutic drug monitoring at 2, 4, and 6 h post-dose may aid in optimizing dosing to achieve the recommended rifampicin concentration of ≥ 8 µg/mL. A higher rifampicin Cmax is required for severe forms TB such as TB meningitis, with Cmax ≥ 22 μg/mL and area under the concentration-time curve (AUC) from time zero to 6 h (AUC6) ≥ 70 μg·h/mL associated with reduced mortality. More studies are needed to confirm whether doses achieving exposures higher than the current standard dosage could translate into faster sputum conversion, higher cure rates, lower relapse rates, and less mortality. It is encouraging that daily rifampicin doses up to 35 mg/kg were found to be safe and well-tolerated over a period of 12 weeks. High-dose rifampicin should thus be considered in future studies when constructing potentially shorter regimens. The studies should be adequately powered to determine treatment outcomes and should include surrogate markers of efficacy such as Cmax/MIC (minimum inhibitory concentration) and AUC/MIC.
引用
- Abulfathi AA, Decloedt EH, Svensson EM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Clin Pharmacokinet. 2019. PMID: 31049868. doi:10.1007/s40262-019-00764-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。